Multiple Myeloma: ESMO Clinical Practice Guidelines
Published in 2017 – Ann Oncol (2017) 28 (suppl 4): iv52–iv61.
Authors: P. Moreau, J. San Miguel, P. Sonneveld, M. V. Mateos, E. Zamagni, H. Avet-Loiseau, R. Hajek, M. A. Dimopoulos, H. Ludwig, H. Einsele, S. Zweegman, T. Facon, M. Cavo, E. Terpos, H. Goldschmidt, M. Attal & C. Buske
Multiple myeloma accounts for 1% of all cancers and approximately 10% of all haematological malignancies. These updated ESMO Clinical Practice Guidelines cover the diagnosis and pathology/molecular biology, staging and risk assessment and response evaluation of multiple myeloma. Treatment recommendations address front-line treatment of both asymptomatic (smouldering or indolent) and symptomatic myeloma, consolidation, maintenance and treatment of relapsed and refractory disease and follow-up, including a list of major treatment regimens. A new supportive care section addresses issues related to the occurrence of multiple myeloma such as bone disease and spinal cord compression; anaemia, bone marrow failure and infections; and renal failure.